Beam Therapeutics reports dosing of the first patient with BEAM-201, a multiplex-edited allogeneic CAR-T cell candidate developed to treat relapsed or...

AvenCell Therapeutics announces that the European Medicines Agency has approved its clinical trial application for AVC-201, a novel CRISPR-edited and...

New research from Carl June’s lab at University of Pennsylvania may be a game-changer for adoptive T cell immunotherapies: by taking the brakes off T...

Founded in 2011, Caribou Biosciences is developing novel allogeneic CAR-T cell and CAR-natural killer cell therapies to treat cancer. The UC Berkeley...

This week’s update looks at a Phase 1/2 study for ALLO-501A, a TALEN-edited CAR T-cell therapy for large B-cell lymphoma.

In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...

Last week, Allogene Therapeutics announced the publication of data from the Phase 1 UNIVERSAL trial of ALLO-715, a TALEN-engineered CAR-T candidate...